Allucent

Rare seizure disorders are complex, influenced by genetics, physiology, and infectious diseases, which makes accurate diagnosis and treatment development a lengthy challenge. However, progress is being made. In a recent blog, Allucent experts Rachel Ham, MSc, Rachel Rozakis, PharmD, and Marcus Delatte, PhD. Delatte explore: 🔸 Examples of rare seizure disorders and their onset 🔸 Current FDA-approved therapies 🔸 Innovations bringing hope to patients and families Read the full blog here: https://lnkd.in/ea7jYeZJ #Allucent #BringingNewTherapiesToLight #RareSeizureDisorders #RareDiseaseTreatment #DrugDevelopment #Neuroscience

Allucent's COO, Patrick Phillips BSc(Hons) D.Phil. and CIO, Nathan Thompson, sat down with the San Francisco Business Times to share how Allucent is leveraging AI with their proprietary Generative AI platform, LucentAI, and other advanced technologies to support biopharma innovators, underscoring the value of combining operational innovation with therapeutic expertise to drive efficient and informed drug development. Our executive A-Team is excited to share more insights with biopharma companies at the 2026 J.P. Morgan Healthcare Conference and discuss how we support sponsors across the development lifecycle. Contact your business development representative and to read the full article, click here: https://lnkd.in/eCMuxwMp

With thousands of active CGT trials and new approvals emerging, this sector is expanding rapidly but complex supply chains, regulatory scrutiny, and clinical holds continue to challenge sponsors. 𝗔 𝟮𝟬𝟮𝟰 𝗙𝗗𝗔 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝘀𝗵𝗼𝘄𝗲𝗱 𝘁𝗵𝗮𝘁 𝗰𝗲𝗹𝗹 𝗮𝗻𝗱 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘁𝗿𝗶𝗮𝗹𝘀 𝗵𝗮𝘃𝗲 𝗮𝗰𝗰𝗼𝘂𝗻𝘁𝗲𝗱 𝗳𝗼𝗿 ~𝟰𝟬% 𝗼𝗳 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗵𝗼𝗹𝗱𝘀 𝗳𝗿𝗼𝗺 𝟮𝟬𝟮𝟬-𝟮𝟬𝟮𝟰, 𝗱𝗲𝘀𝗽𝗶𝘁𝗲 𝗿𝗲𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗶𝗻𝗴 𝗼𝗻𝗹𝘆 𝗮 𝘀𝗺𝗮𝗹𝗹 𝗳𝗿𝗮𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗮𝗹𝗹 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝘁𝘂𝗱𝗶𝗲𝘀. Since then, high-profile holds through 2025 reinforce that this elevated level of regulatory scrutiny and operational risk persists, underscoring the need for tighter coordination and control across trial execution. That’s exactly why smarter Randomization & Trial Supply Management (RTSM) is essential to protect patients, reduce risk, and accelerate breakthroughs. Allucent CGT expert, Monique Muller, MSc shares why traditional RTSM no longer works and the strategies our teams use have developed to drive success for CGT development programs in our recent blog. Click here to read: https://lnkd.in/ebaR9Ybr #Allucent #BringingNewTherapiesToLight #CellAndGeneTherapy #CGT #CGTClinicalTrials #RTSM #VeevaRTSM

𝗖𝗼𝗻𝗻𝗲𝗰𝘁 𝘄𝗶𝘁𝗵 𝗔𝗹𝗹𝘂𝗰𝗲𝗻𝘁'𝘀 𝗖𝗘𝗢 𝗮𝘁 𝗝.𝗣. 𝗠𝗼𝗿𝗴𝗮𝗻 𝟮𝟬𝟮𝟲 Our CEO, Paula Brown Stafford is thrilled to head to JP Morgan Healthcare Conference in San Francisco next week! Schedule a meeting to learn how Allucent's tech-enabled, specialty approach helps mid-size biopharma companies accelerate their drug development programs from early strategy through clinical development and regulatory approval. Contact your business development representative or click here to request a meeting: https://lnkd.in/esgc6Rgj #Allucent #BringingNewTherapiesToLight #ATeam #JPM2026 #JPMorganHealthcareConference #SpecialityCRO #CROPartner

Happy New Year from Allucent! We are incredibly grateful for our dedicated employees and valued customers who share our mission to bring new therapies to patients around the globe. Let's continue to SHINE together in 2026! #Allucent #BringingNewTherapiesToLight #HappyNewYear #2026

Rare disease clinical trials are uniquely challenging, with small patient populations, recruitment barriers, and limited data requiring innovative approaches and expert execution. A-Team expert Milan Marinkov, MD. Executive Medical Director and Rare Disease Medical Lead, wrote a blog to delve into the critical obstacles in rare disease trials and explore how collaboration, adaptive trial designs, and patient-focused methods can pave the way for success for small to mid-size biopharma companies. If you're involved in rare disease drug development, this is a must-read. Check out the blog here: https://lnkd.in/eEyaeHgf #Allucent #BringingNewTherapiesToLight #RareDiseaseClinicalResearch #RareDiseaseDrugDevelopment #RareCRO

Adopting AI in pharmacovigilance (PV) can be transformative for small and mid-size biopharma companies but it’s not without challenges. That’s where a trusted CRO like Allucent steps in, bridging the gap between cutting-edge AI and practical implementation. In our recent blog, Allucent’s Pharmacovigilance A-Team explores the hurdles of AI adoption in PV and how partnering with a CRO can drive success. Discover how Allucent can help you: ▪️ Cut PV costs without compromising quality ▪️ Gain end-to-end support, from implementation to inspection readiness ▪️ Access expertise in drug safety and AI technologies Read the full blog here: https://lnkd.in/eMMJfm8z #Allucent #BringingNewTherapiesToLight #Pharmacovigilance #AI #Biopharma #DrugSafety #CRO

𝗧𝗵𝗲 𝗘𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗥𝗼𝗹𝗲 𝗼𝗳 𝗖𝗔𝗥 𝗧-𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 CAR T-cell therapy is reshaping the treatment landscape for hematologic malignancies, but challenges remain, from clinical resistance to manufacturing complexities. In a recent blog, Oksana Fabri MD PhD, Executive Medical Director of Hematology/Oncology at Allucent, explores: ▪️ Key barriers limiting CAR T-cell success ▪️ Advances in manufacturing and CAR design ▪️ How CAR T fits into the future of precision oncology Read the full blog: #Allucent #BringingNewTherapiesToLight #CARTcellTherapy #Immunotherapy #Hematology #Oncology #PrecisionMedicine

Complete your registration for Allucent's upcoming webinar! https://lnkd.in/eEuyPJ74 Senior Director, Pharmacometrics Jessica K. Roberts Roberts, PhD, MSCI, MBA will explore how modeling and simulation can be used to meet the requirements of the FDA Animal Rule, a regulatory mechanism that enables drug approval based on animal efficacy data. Our expert speaker will share practical insights and real-world examples to help you: - Understand when the Animal Rule is appropriate for drug approval. - Learn how modeling and simulation support PK-based translation from animal efficacy data to human dose selection under the FDA Animal Rule. - Apply these concepts to your own drug development programs. #Allucent #BringingNewTherapiesToLight #Webinar #AnimalRule #DoseSelection #Pharmacometrics #DrugDevelopment #RegulatoryApproval #ModelingAndSimulation

𝗦𝗵𝗶𝗻𝗶𝗻𝗴 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿 𝘁𝗼 𝗖𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗲 𝗖𝘂𝗹𝘁𝘂𝗿𝗮𝗹 𝗕𝗲𝗮𝘂𝘁𝘆 A-Team members from around the world participated in Allucent's Global Photo Contest to share what Cultural Beauty means to them, and the results were incredible! Thanks to everyone who took the time to submit a photo and to everyone who voted, we now have 12 stunning images that will be featured in our 2026 calendar. Congratulations to our photographers whose work was selected, your perspective inspired all of us. And to everyone who participated in any way, thank you for helping us celebrate the diversity and beauty of our global Allucent community. #Allucent #BringingNewTherapiesToLight #CulturalBeauty #ATeam #Photography #GlobalCRO